2012
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA. Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell 2012, 21: 430-446. PMID: 22439938, PMCID: PMC3312044, DOI: 10.1016/j.ccr.2011.12.029.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntimetabolites, AntineoplasticApoptosisAzacitidineBone Marrow CellsBreast NeoplasmsCell CycleCell Line, TumorCell Transformation, NeoplasticDecitabineDNA DamageDNA MethylationDNA Modification MethylasesGene SilencingHumansLeukemiaMiceMolecular Sequence DataNeoplastic Stem CellsPromoter Regions, GeneticSignal TransductionTumor Cells, CulturedConceptsKey cellular regulatory pathwaysDNA methylation inhibitorPromoter DNA hypermethylationCellular regulatory pathwaysDNA demethylating agentEpithelial tumor cellsPromoter DNA methylationRapid DNA damageCancer stem-like cellsGene reexpressionDNA methylationStem-like cellsMethylation inhibitorDNA hypermethylationRegulatory pathwaysCancer therapy approachesAssociated geneDNA damageTumor cellsImmediate cytotoxicityNanomolar dosesTransient exposureCellsGenesMethylation
2009
Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer
Glöckner S, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne A, Smits KM, Bakker C, Jonkers DM, Stockbrügger R, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer. Cancer Research 2009, 69: 4691-4699. PMID: 19435926, PMCID: PMC3062162, DOI: 10.1158/0008-5472.can-08-0142.Peer-Reviewed Original ResearchConceptsTissue factor pathway inhibitor-2Colorectal cancerStool DNATFPI2 methylationStage INonmetastatic colorectal cancerHuman colorectal cancerPotential novel biomarkersCRC patientsNoncancer controlsColorectal carcinogenesisNovel biomarkersUseful adjunctPotential tumor suppressor geneNoninvasive strategyTumor suppressor geneEarly detectionAberrant DNA methylationPatientsFrequent eventCancerAberrant methylationSuppressor geneBiomarkers
2008
Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors
Yi JM, Tsai HC, Glöckner S, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Research 2008, 68: 8094-8103. PMID: 18829568, PMCID: PMC2744404, DOI: 10.1158/0008-5472.can-07-6208.Peer-Reviewed Original ResearchMeSH KeywordsAC133 AntigenAnimalsAntigens, CDAntineoplastic AgentsAzacitidineBrain NeoplasmsCaco-2 CellsCarcinomaColorectal NeoplasmsDecitabineDNA (Cytosine-5-)-MethyltransferasesDNA MethylationFemaleGene DeletionGene Expression Regulation, NeoplasticGlioblastomaGlycoproteinsHCT116 CellsHT29 CellsHumansMiceMice, NudePeptidesTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsDNA methylationMethylation patternsPromoter DNA methylation patternsHistone modification marksDNA methylation patternsDNA methylation changesDNA methylation statusPromoter CpG islandsAberrant DNA methylationAbnormal DNA methylationCultured colon cancerStem-like cell populationTranscription stateModification marksPromoter signaturesCpG islandsSuch methylationIndividual cell linesMethylation changesAberrant genesDifferentiated progenyMethylationMarker proteinsMethylation statusGenes
2000
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota M, Ohe-Toyota M, Ahuja N, Issa J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 710-715. PMID: 10639144, PMCID: PMC15395, DOI: 10.1073/pnas.97.2.710.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaBase SequenceColorectal NeoplasmsCpG IslandsDNA MethylationDNA Mutational AnalysisDNA, NeoplasmGenes, p16Genes, p53Genes, rasHumansMicrosatellite RepeatsMutationPhenotypePoint MutationPolymorphism, Single-Stranded ConformationalProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSequence DeletionTumor Cells, CulturedConceptsCpG island methylator phenotypeColorectal cancerK-RAS mutationsDifferent genetic lesionsActivation of oncogenesTumor suppressor geneMultiple CpG islandsColorectal tumorsMethylator phenotypeCpG islandsDistinct genetic profilesP53 mutationsEpigenetic alterationsMolecular diversitySuppressor geneGenetic lesionsNovel pathwayGroup of tumorsGenetic alterationsK-RASMutationsCancer developmentSimultaneous methylationGenes
1999
CpG island methylator phenotype in colorectal cancer
Toyota M, Ahuja N, Ohe-Toyota M, Herman J, Baylin S, Issa J. CpG island methylator phenotype in colorectal cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 8681-8686. PMID: 10411935, PMCID: PMC17576, DOI: 10.1073/pnas.96.15.8681.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAge FactorsCarrier ProteinsCloning, MolecularColorectal NeoplasmsCpG IslandsDNA MethylationDNA RepairGenes, p16Genes, Tumor SuppressorHumansMicrosatellite RepeatsMutL Protein Homolog 1Neoplasm ProteinsNuclear ProteinsPhenotypePolymerase Chain ReactionSulfitesTumor Cells, CulturedConceptsCpG island methylator phenotypeColorectal cancerMethylator phenotypeSporadic colorectal cancerMismatch repair deficiencyCpG islandsAge-dependent mannerNormal colonic cellsCpG island amplificationHigh incidenceColon cancerTHBS1 methylationNormal colonPromoter region CpG islandsSporadic tumorsCancerMicrosatellite instabilityColonic cellsTumor suppressor geneCpG island methylationRepair deficiencyCancer-specific mannerHMLH1 methylationCell linesTranscriptional inactivationMethylation and silencing of the Thrombospondin-1 promoter in human cancer
Li Q, Ahuja N, Burger P, Issa J. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene 1999, 18: 3284-3289. PMID: 10359534, DOI: 10.1038/sj.onc.1202663.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCaco-2 CellsCpG IslandsDNA MethylationGlioblastomaHL-60 CellsHumansJurkat CellsPromoter Regions, GeneticThrombospondin 1Tumor Cells, CulturedConceptsGlioblastoma multiformeTHBS1 expressionThrombospondin-1De novo methylationHuman cancersCell linesPrimary glioblastoma multiformeMethylation-associated inactivationNovo methylationCpG islandsPrimary tumorCpG sitesAngiogenesis inhibitorsTHBS1 methylationMethylation statusMolecular defectsHuman neoplasmsMethylationHuman tumorsDetectable expressionCancerTumorsExpressionCommon featureSilencing